Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APPB-429
- Development stage
- Preclinical
- Lead developer
- Applied Biologics
- Modality
- Gene Therapies
01
Overview
APPB-429 is an investigational gene therapy program being developed by Applied Biologics for the treatment of diabetic peripheral neuropathy (DPN). Designed as a locally administered gene therapy, APPB-429 is engineered to deliver sustained regenerative, neurotrophic, and protective biological signals directly within the affected lower extremity. The therapeutic strategy aims to enable local cells to produce selected naturally occurring human proteins that promote peripheral nerve regeneration, restore nerve function, and modulate the inflammatory environment that impairs natural nerve repair.
Beyond the preview
Go deeper on APPB-429.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APPB-429.